US Edition
ELVN-001 shows cancer-killing potential for CML in Phase 1 study
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ELVN-001 shows cancer-killing potential for CML in Phase 1 study
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients who’ve previously received other treatments, according to data from an ongoing Phase 1 trial. Enliven Therapeutics, the company developing ELVN-001, will be presenting interim findings from the trial next month at the European Hematology Association 2025 Congress, in an…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
